Spermicide by Columbia Labs Fails to Stop HIV in Clinical Trial
A clinical trial sponsored by the United Nations group UNAIDS, using 700 prostitutes in South Africa and other developing countries, has ended in bitter disappointment after about 100 women included in the study of Columbia Laboratories Inc.'s spermicide contracted HIV.
Researchers hoped the spermicide would prevent transmission of the virus that causes AIDS. But in a bewildering development, the group of patients in the experiment whose members received a placebo (the vaginal cream Replens) appeared to show a somewhat lower HIV infection rate than those using the once-promising spermicide.
The company's spermicidal gel, called Advantage-S, in earlier Phase I and Phase II studies had held the promise of blocking HIV transfer.
Officials of UNAIDS involved in the study couldn't be reached.
The clinical study was conducted on 700 women working as prostitutes in South Africa, Thailand, Ivory Coast, and a fourth African country between 1996 and May 2000, Mr. Bologna said in an interview. The women were randomly assigned to eight groups in the double-blind test, with half getting the placebo and half receiving the Advantage-S spermicide, which uses a lower-than-normal concentration of a drug known as Nonoxynol-9. Mr. Bologna said all women in the UNAIDS study were provided with condoms and encouraged to get clients to use them. He said the women were asked to keep diaries overseen by monitors to track how they used the drugs and condoms.
Nonoxynol-9 is a common ingredient in spermicide in the U.S., but Columbia, a Miami pharmaceuticals company, used technology to increase the efficacy so it could be used at a lower dose, Mr. Bologna said. According to the World Health Organization, Nonoxynol-9, which has been available for many years and was generally considered safe, kills HIV in the test tube and provides a physical, "gooey" barrier that sperm and microbes cannot penetrate. However, higher concentrations of the drug have recently been found to cause vaginal lesions, which can then be entry points for HIV. Health experts have warned against overuse of the drug, particularly by prostitutes who might apply it repeatedly during a single evening.
The clinical trial was ended recently after the number of women testing positive for HIV reached 100 of the 700 women in the study. "It is unfortunate for the poor women in Africa, because we thought we had a product that worked," Mr. Bologna said. "They need a product like this because men aren't going to use condoms."
Mr. Bologna defended the ethics of using a group of largely illiterate prostitutes for the test. "There was a lot of debate about the issues involved. The reality is, if you're going to help these women, you have to conduct the tests on them. Mary Jane in Ohio is not at high risk for the transfer of HIV. It's these poor women in Africa."
Moreover, he said a drug-safety monitoring board had worked closely with UNAIDS to make sure the patients' interests were observed. "Obviously, everyone tried to do this to the highest ethical standards."
In 4 p.m. American Stock Exchange trading Monday, Columbia fell 56%. In March, shares of Columbia soared after news that an interim analysis of the trial indicated one group of patients in the double-blind trial was doing better than the other. Mr. Bologna said "people assumed" that the group doing better in the study was the one using the spermicide. As it turned out, the placebo group appears to have done better, although Mr. Bologna cautioned that those results may not be scientifically meaningful.
Back to the Women Alive Spring 2000 Contents Page.
This article was provided by Women Alive. It is a part of the publication Women Alive Newsletter.